Stay updated on Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    Major update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.
    Difference
    2%
    Check dated 2025-10-05T10:04:40.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    Updated the page revision from v3.0.2 to v3.1.0.
    Difference
    0.1%
    Check dated 2025-09-28T03:11:43.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    Version updated from v3.0.1 to v3.0.2, indicating a new release in the core content. The 'Back to Top' element was removed, with no other substantive changes detected.
    Difference
    0.1%
    Check dated 2025-09-13T17:11:02.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-09-06T14:55:46.000Z thumbnail image
  8. Check
    63 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the addition of a facility name and location, as well as the introduction of new drug names such as Eribulin Mesylate and Pembrolizumab. However, several related topics and terms have been removed, including previous mentions of Eribulin and Pembrolizumab.
    Difference
    2%
    Check dated 2025-08-30T11:44:39.000Z thumbnail image
  9. Check
    77 days ago
    Change Detected
    Summary
    The web page has been updated from version v2.16.11 to v2.16.12.
    Difference
    0.1%
    Check dated 2025-08-16T04:36:25.000Z thumbnail image

Stay in the know with updates to Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.